Cheng, Pin-NanPin-NanChengFeng, I-CherI-CherFengChen, Jyh-JouJyh-JouChenKuo, Hsing-TaoHsing-TaoKuoLee, Pei-LunPei-LunLeeYu, Ming-LungMing-LungYuChiu, Yen-ChengYen-ChengChiuChiu, Hung-ChihHung-ChihChiuChien, Shih-ChiehShih-ChiehChienPEI-JER CHENCHUN-JEN LIU2024-01-102024-01-102024-0102692813https://scholars.lib.ntu.edu.tw/handle/123456789/638382Lipid-lowering effect was observed during treatment with tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB). However, the metabolic features in patients switching from TDF to tenofovir alafenamide (TAF) remain unclear.enblood lipid; hepatitis B virus; insulin resistance; tenofovir alafenamide[SDGs]SDG3Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis Bjournal article10.1111/apt.17765378458152-s2.0-85174301509https://api.elsevier.com/content/abstract/scopus_id/85174301509